Natalizumab and Chronic Inflammation

Summary

Natalizumab and Chronic Inflammation is a clinical trial^[1].

Key Facts

• Natalizumab and Chronic Inflammation is in the country of United States^[2].
• Natalizumab and Chronic Inflammation's instance of is recorded as clinical trial^[3].
• Natalizumab and Chronic Inflammation's start time is recorded as +2022-01-01T00:00:00Z^[4].
• Natalizumab and Chronic Inflammation's end time is recorded as +2023-12-31T00:00:00Z^[5].
• Natalizumab and Chronic Inflammation's main subject is recorded as sclerosis^[6].
• Natalizumab and Chronic Inflammation's main subject is recorded as multiple sclerosis^[7].
• Natalizumab and Chronic Inflammation's number of participants is recorded as {'unit': '1', 'amount': '+36'}^[8].
• Natalizumab and Chronic Inflammation's title is recorded as Assessing the Effect of Natalizumab of Magnetic Resonance Imaging Measures of Blood Brain Barrier Permeability and Myelin Integrity^[9].
• Natalizumab and Chronic Inflammation's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Natalizumab and Chronic Inflammation's ClinicalTrials.gov ID is recorded as NCT05177718^[11].
• Natalizumab and Chronic Inflammation's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Natalizumab and Chronic Inflammation's research intervention is recorded as natalizumab^[13].
• Natalizumab and Chronic Inflammation's research intervention is recorded as immunologic factor^[14].
• Natalizumab and Chronic Inflammation's clinical trial phase is recorded as phase IV clinical trial^[15].
• Natalizumab and Chronic Inflammation's research site is recorded as Vanderbilt University Medical Center^[16].
• Natalizumab and Chronic Inflammation's research subject recruitment status is recorded as recruiting^[17].
• Natalizumab and Chronic Inflammation's study type is recorded as interventional study^[18].